title: Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings.
abstract: The vast majority of people living with human immunodeficiency virus (HIV)/acquired immune deficiency syndrome reside in the developing world, in settings characterized by limited health budgets, critical shortages of doctors, limited laboratory monitoring, a substantial burden of HIV in children, and high rates of coinfection, in particular tuberculosis. Therefore, the extent to which new antiretrovirals will contribute to improvements in the management of HIV globally will depend to a large extent on their affordability, ease of use, low toxicity profile, availability as pediatric formulations, and compatibility with tuberculosis and other common drugs. We undertook a systematic review of the available evidence regarding drug interactions, and the efficacy and safety of rilpivirine (also known as TMC-278), and assessed our findings in view of the needs and constraints of resource-limited settings. The main pharmacokinetic interactions relevant to HIV management reported to date include reduced bioavailability of rilpivirine when coadministered with rifampicin, rifabutin or acid suppressing agents, and reduced bioavailability of ketoconazole. Potential recommendations for dose adjustment to compensate for these interactions have not been elaborated. Trials comparing rilpivirine and efavirenz found similar outcomes up to 96 weeks in intent-to-treat analysis; failure of rilpivirine was mainly virological, whereas failure among those exposed to efavirenz was mainly related to the occurrence of adverse events. Around half of the patients who fail rilpivirine develop non-nucleoside reverse transcriptase inhibitor resistance mutations. The incidence of Grade 2-4 events was lower for rilpivirine compared with efavirenz. Grade 3-4 adverse events potentially related to the drugs were infrequent and statistically similar for both drugs. No dose-response relationship was observed for efficacy or safety, and the lowest dose (25 mg) was selected for further clinical development. The potential low cost and dose of the active pharmaceutical ingredient means that rilpivirine can potentially be manufactured at a low price. Moreover, its long half-life suggests the potential for monthly dosing via nonoral routes, with promising early results from studies of a long-acting injectable formulation. These characteristics make rilpivirine an attractive drug for resource-limited settings. Future research should assess the potential to improve robustness and assess the clinical significance of interaction with antituberculosis drugs.
authors.affiliation: Médecins Sans Frontières, Geneva, Switzerland.
authors.forename: Nathan
authors.initials: N
authors.lastname: Ford
authors.forename: Janice
authors.initials: J
authors.lastname: Lee
authors.forename: Isabelle
authors.initials: I
authors.lastname: Andrieux-Meyer
authors.forename: Alexandra
authors.initials: A
authors.lastname: Calmy
references.citation: N Engl J Med. 2010 Dec 30;363(27):2587-99
references.pmid: 21091279
references.citation: Eur J Pharm Biopharm. 2009 Aug;72(3):502-8
references.pmid: 19328850
references.citation: J Med Chem. 2005 Mar 24;48(6):1901-9
references.pmid: 15771434
references.citation: JAMA. 2011 Jan 12;305(2):191-2
references.pmid: 21224461
references.citation: Ann Pharmacother. 2010 Jan;44(1):157-65
references.pmid: 19996323
references.citation: Antivir Ther. 2009;14(5):713-22
references.pmid: 19704175
references.citation: AIDS. 2006 Aug 22;20(13):1745-52
references.pmid: 16931939
references.citation: Expert Opin Pharmacother. 2009 Oct;10(15):2445-66
references.pmid: 19678794
references.citation: AIDS. 2010 Jun 19;24(10):1461-70
references.pmid: 20479637
references.citation: AIDS. 2010 Jan 2;24(1):55-65
references.pmid: 19926964
references.citation: Antimicrob Agents Chemother. 2010 May;54(5):2042-50
references.pmid: 20160045
references.citation: Lancet. 2008 Jul 26;372(9635):293-9
references.pmid: 18657708
references.citation: AIDS. 2006 Aug 22;20(13):1721-6
references.pmid: 16931936
references.citation: Drugs Today (Barc). 2011 Jan;47(1):5-15
references.pmid: 21373646
references.citation: Clin Infect Dis. 2010 May 15;50 Suppl 3:S245-54
references.pmid: 20397955
references.citation: Expert Opin Investig Drugs. 2009 Jul;18(7):1035-41
references.pmid: 19548857
references.citation: Eur J Pharm Biopharm. 2008 Nov;70(3):853-60
references.pmid: 18657611
references.citation: PLoS Med. 2006 Nov;3(11):e438
references.pmid: 17121449
references.citation: Science. 2010 Sep 3;329(5996):1168-74
references.pmid: 20643915